<SEC-DOCUMENT>0001171843-15-005339.txt : 20150929
<SEC-HEADER>0001171843-15-005339.hdr.sgml : 20150929
<ACCEPTANCE-DATETIME>20150929080519
ACCESSION NUMBER:		0001171843-15-005339
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150925
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150929
DATE AS OF CHANGE:		20150929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		151128888

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>document.htm
<DESCRIPTION>FORM 8-K FILING DOCUMENT
<TEXT>
<!DOCTYPE html
	PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN"
	"http://www.w3.org/TR/html4/loose.dtd">

<html lang="en-US">

	<head>
		<title>Form 8-K Filing</title>
	</head>

	<body>
		<p align="center"><font size="5"><b>UNITED STATES<br>
					SECURITIES AND EXCHANGE COMMISSION<br>
				</b></font></p>
		<p align="center"><font size="3"><b>Washington, D.C. 20549</b><br>
			</font></p>
		<hr noshade="1" width="150" align="center">
		<p align="center"><font size="5"><b>FORM 8-K</b><br>
			</font></p>
		<hr noshade="1" width="150" align="center">
		<p align="center"><font size="3"><b>CURRENT REPORT</b><br>
			</font></p>
		<p align="center"><font size="3"><b>Pursuant to Section&nbsp;13 or 15(d) of<br>
					The Securities Exchange Act of 1934</b><br>
			</font></p>
		<p align="center"><font size="3">Date of Report (Date of earliest event reported): <b>September 25, 2015</b>&nbsp; <br>
			</font></p>
		<hr noshade="1" width="150" align="center">
		<p align="center"><font size="5"><b>BioCryst Pharmaceuticals, Inc.</b></font><br>
			<font size="2">(Exact name of registrant as specified in its charter) </font></p>
		<!-- Registrant's State of Inc, File and IRS Number -->
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="33%" align="center"><font size="2"><b>Delaware</b></font></td>
				<td width="34%" align="center"><font size="2"><b>000-23186</b></font></td>
				<td width="33%" align="center"><font size="2"><b>62-1413174</b></font></td>
			</tr>
			<tr valign="top">
				<td width="33%" align="center"><font size="2">(State or other jurisdiction<br>
						of incorporation) </font></td>
				<td width="34%" align="center"><font size="2">(Commission File Number) </font></td>
				<td width="33%" align="center"><font size="2">(IRS Employer Identification No.) </font></td>
			</tr>
		</table>
		<!-- Registrant's Postal Addess and Zip Code --><br>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="50%" align="center"><font size="2"><b>4505 Emperor Blvd., Suite 200<br>
Durham, North Carolina </b></font></td>
				<td width="50%" align="center" valign="bottom"><font size="2"><b>27703</b></font></td>
			</tr>
			<tr valign="top">
				<td width="50%" align="center"><font size="2">(Address of principal executive offices) </font></td>
				<td width="50%" align="center"><font size="2">(Zip Code) </font></td>
			</tr>
		</table>
		<p align="center"><font size="2">Registrant's telephone number, including area code: &nbsp; <b>(919) 859-1302</b></font></p>
		<p align="center"><font size="2">
			________________________________________________________________________________<br>
			(Former name or former address, if changed since last report)</font></p>
		<!-- Simultaneous filing obligation checkboxes -->
		<p><font size="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td nowrap><font size="2">&nbsp; &nbsp;</font></td>
				<td nowrap="1"><font size="2">[ &nbsp;&nbsp;] &nbsp;</font></td>
				<td><font size="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></td>
			</tr>
			<tr valign="top">
				<td nowrap><font size="2">&nbsp; &nbsp;</font></td>
				<td nowrap="1"><font size="2">[ &nbsp;&nbsp;] &nbsp;</font></td>
				<td><font size="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></td>
			</tr>
			<tr valign="top">
				<td nowrap><font size="2">&nbsp; &nbsp;</font></td>
				<td nowrap="1"><font size="2">[ &nbsp;&nbsp;] &nbsp;</font></td>
				<td><font size="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></td>
			</tr>
			<tr valign="top">
				<td nowrap><font size="2">&nbsp; &nbsp;</font></td>
				<td nowrap="1"><font size="2">[ &nbsp;&nbsp;] &nbsp;</font></td>
				<td><font size="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></td>
			</tr>
		</table>
		<br>
		<hr noshade="1">
		<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%"></div>

		<p><font size="3"><b><p><font size="3"><b>Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></font></p></b></font></p>
		<p><font size="2"><P >
	On September 25, 2015, the Board of Directors (the &#034;Board&#034;) of BioCryst Pharmaceuticals, Inc. (the &#034;Company&#034;) voted to increase the size of the Board from eight directors to nine directors and elected Sanj K. Patel to fill the vacancy created by the enlargement of the Board.  The Company issued a news release reporting this matter on September 29, 2015, and a copy of the news release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.</P>
<P >
	 </P>
<P >
	The Company&#039;s Board of Directors also appointed Mr. Patel to serve on the Finance Committee effective upon his election to the Board of Directors.</P>
<P >
	 </P>
<P >
	Pursuant to the Company&#039;s Stock Incentive Plan, Mr. Patel will receive an automatic grant of 16,667 stock options upon joining the Board of Directors, and will be entitled to a grant of 15,000 stock options after each annual stockholders&#039; meeting.  Mr. Patel will receive compensation consistent with the Company&#039;s director compensation policy as described in the Company&#039;s proxy statement for its 2015 annual meeting of stockholders. </P>
</font></p>

		<p><font size="3"><b><p><font size="3"><b>Item 9.01. Financial Statements and Exhibits.</b></font></p></b></font></p>
		<p><font size="2"><p>
	<font style="font-size: 12px"><font style="font-family: times new roman,times,serif"><strong>(d) Exhibits</strong></font></font></p>
<table border="0" cellpadding="0" cellspacing="0" width="660">

		<tr height="21">
			<td height="21" width="99">
				<font style="font-size: 12px"><font style="font-family: times new roman,times,serif"><strong><u>Exhibit No.</u></strong></font></font></td>
			<td width="561">
				<font style="font-size: 12px"><font style="font-family: times new roman,times,serif"><strong><u>Description</u></strong></font></font></td>
		</tr>
		<tr height="38">
			<td height="38" valign="top" width="99">
				<font style="font-size: 12px"><font style="font-family: times new roman,times,serif">99.1</font></font></td>
			<td valign="top" width="561">
				<font style="font-size: 12px"><font style="font-family: times new roman,times,serif">Press Release dated September 29, 2015 entitled &quot;Sanj K. Patel Appointed to BioCryst&#39;s Board of Directors&quot;</font></font></td>
		</tr>

</table>
</font></p>
		<hr noshade="1">
		<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%"></div>
		<!-- Registrant's Signature -->
		<p align="center"><font size="3"><b>SIGNATURE</b> </font></p>
		<p><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font></p>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="47%">&nbsp;</td>
				<td width="5%">&nbsp;</td>
				<td width="47%" align="center"><font size="2"><b>BioCryst Pharmaceuticals, Inc.</b>
					<hr noshade>
					(Registrant)</font><br>
					<br>
				</td>
			</tr>
			<tr valign="top">
				<td width="47%" align="center"><font size="2"><b>September 29, 2015</b>
					<hr noshade>
					(Date)</font></td>
				<td width="5%">&nbsp;</td>
				<td width="47%" align="center"><font size="2"><b>/s/ &nbsp; ALANE BARNES</b></font>
					<hr noshade>
					<font size="2">Alane Barnes</font><br>
					<font size="2"><i>Vice President, General Counsel,<br> and Corporate Secretary</i></font></td>
			</tr>
		</table>
		<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%"></div>
		<hr />
<p style="text-align: center">
	<strong>EXHIBIT INDEX</strong></p>
<p>
	 </p>
<table border="0" cellpadding="0" cellspacing="0" width="660">

		<tr height="21">
			<td height="21" width="99">
				<font style="font-size: 12px"><font style="font-family: times new roman,times,serif"><strong><u>Exhibit No.</u></strong></font></font></td>
			<td width="561">
				<font style="font-size: 12px"><font style="font-family: times new roman,times,serif"><strong><u>Description</u></strong></font></font></td>
		</tr>
		<tr height="32">
			<td height="32" valign="top" width="99">
				<font style="font-size: 12px"><font style="font-family: times new roman,times,serif">99.1</font></font></td>
			<td width="561">
				<font style="font-size: 12px"><font style="font-family: times new roman,times,serif">Press Release dated September 29, 2015 entitled &quot;Sanj K. Patel Appointed to BioCryst&#39;s Board of Directors&quot;</font></font></td>
		</tr>

</table>

	</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>newsrelease.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>Sanj K. Patel Appointed to BioCryst's Board of Directors</title></head><body><p align="right">EXHIBIT 99.1</p><h3 align="center">Sanj K. Patel Appointed to BioCryst's Board of Directors</h3><p>RESEARCH TRIANGLE PARK, N.C., Sept. 29, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that Sanj K. Patel was elected to the Company's Board of Directors.</p><p>
	"On behalf of the Board of Directors and Leadership Team of BioCryst, I am delighted to welcome Sanj Patel to the Company's Board," said George B. Abercrombie, Chairman of the Board of BioCryst.&#160;"Mr. Patel has a proven track record of successfully developing and commercializing new products for rare diseases, and a deep interest in providing breakthrough treatments for these patients.&#160;He has leveraged his broad experience base in R&amp;D, marketing and sales to grow and build companies that benefit patients and generate extraordinary value for all stakeholders."</p><p>
	Sanj Patel formed Synageva in June 2008 and was its President &amp; Chief Executive Officer through the company's $8.4 billion acquisition by Alexion Pharmaceuticals in June 2015.&#160;While at Genzyme Corporation from 1999 through June 2008, Sanj held leadership roles of increasing responsibility, including Vice President, Head of Sales, Marketing &amp; Commercial Operations. He is the Chairman and CEO of Kiniksa Pharmaceuticals, a privately-held biotechnology company.</p><p>
	"In recent years, I have gotten to know the BioCryst team, and we share a passion for developing and commercializing novel treatments for rare diseases.&#160;With results from two clinical trials for the prevention of hereditary angioedema attacks expected in 2015, it is an exciting time to join the BioCryst Board of Directors," said Mr. Sanj Patel.&#160;"I look forward to working with the Board and the BioCryst Leadership Team as the Company advances toward commercialization of oral treatments for rare disease."</p><p>
	<strong>About BioCryst Pharmaceuticals </strong></p><p>
	BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases.&#160; BioCryst's ongoing development programs include oral plasma kallikrein inhibitors for hereditary angioedema; Avoralstat, BCX7353 and other second generation compounds, and BCX4430, a broad spectrum viral RNA polymerase inhibitor. For more information, please visit the Company's website at www.BioCryst.com.&#160;</p><p>
	This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.</p><p>
	BCRXW</p><pre>CONTACT: Robert Bennett
         BioCryst Pharmaceuticals
         +1-919-859-7910
         (investors &amp; media)</pre></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
